Feburic 80 mg 90 tablets

Tradename:

Feburic 80

Feburic 80

Compound:

Each tablet contains:

80 mg febuxostat

Auxiliary components:

lactose monohydrate hyprolose; microcrystalline cellulose, croscarmellose sodium, magnesium stearate, colloidal silicon dioxide, aqueous.

Properties:

The enzyme xanthine oxidase catalyzes two steps of purine metabolism: the oxidation of hypoxanthine to xanthine and then the oxidation of xanthine to uric acid.

The use of febuxostat leads to a more effective decrease in the concentration of uric acid and maintenance of its level in the blood serum compared with allopurinol.

When using febuxostat for the prevention and treatment of tumor disintegration syndrome, a more intense and rapid decrease in the concentration of uric acid in the blood serum was observed compared with allopurinol.

Indications:

Chronic hyperuricemia in conditions accompanied by the deposition of urate crystals (in the presence of tophi and / or gouty arthritis, including a history).

Treatment and prevention of hyperuricemia in adult patients during cytostatic therapy of hemoblastoses with a moderate to high risk of developing tumor disintegration syndrome (only for a dosage of 120 mg).

Febuxostat is intended for use in adults.

Dosage and administration:

The method of application and dosing regimen of a particular drug depends on its form of release and other factors. The optimal dosage regimen is determined by the doctor. Compliance of the dosage form of a particular drug with indications for use and dosing regimen should be strictly observed.

Taken inside.

The dose is 80-120 mg 1 time / day. The duration of treatment is set individually, depending on the indications.

The goal of treatment is to lower and maintain serum uric acid levels below 6 mg/dL (357 µmol/L).

Contraindications:

Pregnancy, breastfeeding period; children’s age up to 18 years; hypersensitivity to febuxostat.

Precautionary measures:

Febuxostat should only be started after an acute attack of gout has resolved. The use of febucostat can provoke the development of an acute attack of gout due to the release of urate from tissue depots and a subsequent increase in the concentration of uric acid in the blood serum. For the prevention of gout attacks, the simultaneous use of NSAIDs or colchicine for at least 6 months is recommended.

At the beginning of the use of febuxostat and periodically in the presence of clinical manifestations, it is recommended to monitor liver function.

Influence on the ability to drive vehicles and mechanisms

When using febuxostat, drowsiness, dizziness, paresthesia and blurred vision may occur, and, as a result, a decrease in reaction and ability to concentrate, therefore, during the period of treatment, care should be taken when driving vehicles and engaging in other potentially hazardous activities that require concentration and speed of psychomotor reactions.

Side effects:

From the nervous system: often – headache; infrequently – dizziness, paresthesia, hemiparesis, drowsiness, change in taste perception, hypesthesia, hyposmia (weakening of smell).

Respiratory system: cough, bronchitis.

Hematopoietic system: leukopenia, anemia, thrombocytopenia.

Cardiovascular system: angina pectoris, arrhythmias, arterial hypertension.

Digestive system: nausea, diarrhea.

Musculoskeletal system: arthralgia, myalgia.

Dermatological reactions: dermatitis, urticaria, alopecia.

Urinary system: hematuria, polyuria, renal failure, nephrolithiasis.

Reproductive system: erectile dysfunction, gynecomastia, mastalgia.

Allergic reactions.

Storage method:

In a dry cool place at a temperature not exceeding 30 degrees.

Package:

The cardboard box contains 1 blister of 7 or 10 tablets.